(function(){var loadHandler=window['sl_{FA5FD24E-B284-45DA-9AF0-EFB2D448B75A}'];loadHandler&&loadHandler(8, '<div id="spr0_5cf6d131"><div id="spr1_5cf6d131" class="kern slide"><img id="img3_5cf6d131" src="data/img1.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_5cf6d131" class="kern slide"><img id="img0_5cf6d131" src="data/img2.png" width="721.48" height="100.8" alt="" style="left:-1.48px;"/><div id="svg1_5cf6d131" style="left:-1.48px;top:99.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#c76c02" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><div id="svg2_5cf6d131" style="left:-1.48px;top:0.523px;"><svg width="722" height="4" viewBox="0 0 722 4"><path fill="#2e3546" d="M0,0 h721.48 v3.6 h-721.48 Z"/></svg></div><img id="img1_5cf6d131" src="data/img3.png" width="721.48" height="43.101" alt="" style="top:496.899px;"/><div id="spr3_5cf6d131" style="left:657.715px;top:499.855px;"><img id="img2_5cf6d131" src="data/img4.png" width="56" height="36" alt="CHRC logo_with text.psd" style="left:-0.105px;top:-0.177px;"/></div><div id="spr4_5cf6d131" style="left:-6.495px;top:20.107px;"><div style="width:0px;"><span id="txt0_5cf6d131" data-width="164.419922" style="left:277.687px;top:5.644px;">Summary</span></div></div><div id="spr5_5cf6d131" style="left:36.814px;top:121.936px;"><div style="width:0px;"><span id="txt1_5cf6d131" class="nokern relpos" style="left:7.2px;top:5.785px;"></span><span id="txt2_5cf6d131" class="relpos" data-width="407.175781" style="left:21.389px;top:5.143px;">Despite best-evidence-based treatment,</span><span id="txt3_5cf6d131" class="relpos" data-width="187.605469" style="left:21.384px;top:5.143px;"> high-risk and very</span></div><div style="width:0px;"><span id="txt4_5cf6d131" data-width="538.658203" style="left:34.2px;top:38.743px;">high risk patients continue to experience CVD events</span></div></div><div id="spr6_5cf6d131" style="left:36.814px;top:121.936px;"><div style="width:0px;"><span id="txt5_5cf6d131" class="nokern relpos" style="left:7.2px;top:79.705px;"></span><span id="txt6_5cf6d131" class="relpos" data-width="483.697266" style="left:21.389px;top:79.063px;">Failure to attain guideline-recommended LDL-C</span><span id="txt7_5cf6d131" class="relpos" data-width="116.169922" style="left:21.384px;top:79.063px;"> goals is an</span></div><div style="width:0px;"><span id="txt8_5cf6d131" data-width="467.099609" style="left:34.2px;top:112.663px;">important component of this residual CVD risk</span></div></div><div id="spr7_5cf6d131" style="left:36.814px;top:121.936px;"><div style="width:0px;"><span id="txt9_5cf6d131" class="nokern relpos" style="left:7.2px;top:153.625px;"></span><span id="txt10_5cf6d131" class="relpos" data-width="265.425781" style="left:21.389px;top:152.983px;">Additional LDL-C lowering</span><span id="txt11_5cf6d131" class="relpos" data-width="358.736328" style="left:21.384px;top:152.983px;"> options are needed to address this</span></div><div style="width:0px;"><span id="txt12_5cf6d131" data-width="196.574219" style="left:34.2px;top:186.583px;">unmet clinical need</span></div></div><div id="spr8_5cf6d131" style="left:36.814px;top:121.936px;"><div style="width:0px;"><span id="txt13_5cf6d131" class="nokern relpos" style="left:7.2px;top:227.545px;"></span><span id="txt14_5cf6d131" class="relpos" data-width="498.996094" style="left:21.389px;top:226.903px;">The data from clinical trials with PCSK9 inhibition</span></div><div style="width:0px;"><span id="txt15_5cf6d131" data-width="576.925781" style="left:34.2px;top:260.503px;">demonstrate efficacy and safety of LDL-C lowering by an</span></div><div style="width:0px;"><span id="txt16_5cf6d131" data-width="610.244141" style="left:34.2px;top:294.103px;">additional 60% on top of statin ± ezetimibe therapy resulting</span></div><div style="width:0px;"><span id="txt17_5cf6d131" data-width="299.906250" style="left:34.2px;top:327.703px;">in further reductions in MACE</span></div></div></div></div>');})();